Minamide T, Minakata N, Yamashita R, Sakashita S, Yoda Y, Ohashi A
DEN Open. 2025; 5(1):e70077.
PMID: 39991264
PMC: 11843471.
DOI: 10.1002/deo2.70077.
Malcolm J, Bridge K, Holding A, Brackenbury W
BMC Genomics. 2025; 26(1):59.
PMID: 39838295
PMC: 11748566.
DOI: 10.1186/s12864-025-11216-6.
Kim T, Ko S
Nutrients. 2025; 16(24.
PMID: 39770941
PMC: 11677055.
DOI: 10.3390/nu16244320.
Xiong Y, Li J, Jiang X, Zhen W, Ma X, Lin W
Adv Sci (Weinh). 2025; 12(8):e2413518.
PMID: 39742392
PMC: 11848595.
DOI: 10.1002/advs.202413518.
Fang J, Rao X, Wang C, Wang Y, Wu C, Zhou R
Front Pharmacol. 2024; 15:1471476.
PMID: 39737074
PMC: 11683128.
DOI: 10.3389/fphar.2024.1471476.
The Rationale for Combining Hypofractionated Radiation and Hyperthermia.
Sinha P, Folefac C, Overgaard J, Horsman M
Cancers (Basel). 2024; 16(23).
PMID: 39682105
PMC: 11640455.
DOI: 10.3390/cancers16233916.
Non-coding RNAs modulation in breast cancer radioresponse: mechanisms and therapeutic implications.
Moqadami A, Ghafari S, Khalaj-Kondori M
Strahlenther Onkol. 2024; .
PMID: 39545960
DOI: 10.1007/s00066-024-02317-4.
Impact of Hypoxia and the Levels of Transcription Factor HIF-1α and JMJD1A on Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma Cell Lines.
von Fournier A, Wilhelm C, Tirtey C, Stoth M, Ehret Kasemo T, Hackenberg S
Cancer Genomics Proteomics. 2024; 21(6):591-607.
PMID: 39467631
PMC: 11534036.
DOI: 10.21873/cgp.20476.
Cancer cell membrane-coated siRNA-Decorated Au/MnO nanosensitizers for synergistically enhanced radio-immunotherapy of breast cancer.
Wang D, Lin S, Li T, Yang X, Zhong X, Chen Q
Mater Today Bio. 2024; 29:101275.
PMID: 39403312
PMC: 11471673.
DOI: 10.1016/j.mtbio.2024.101275.
Assessing tumor microstructure with time-dependent diffusion imaging: Considerations and feasibility on clinical MRI and MRI-Linac.
Jokivuolle M, Mahmood F, Madsen K, Harbo F, Johnsen L, Lundell H
Med Phys. 2024; 52(1):346-361.
PMID: 39387639
PMC: 11700005.
DOI: 10.1002/mp.17453.
Data Science Opportunities To Improve Radiotherapy Planning and Clinical Decision Making.
Deasy J
Semin Radiat Oncol. 2024; 34(4):379-394.
PMID: 39271273
PMC: 11698470.
DOI: 10.1016/j.semradonc.2024.07.012.
Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action.
OConnor J, Tessyman V, Little R, Babur M, Forster D, Latif A
Cancer Res Commun. 2024; 4(10):2565-2574.
PMID: 39240065
PMC: 11443776.
DOI: 10.1158/2767-9764.CRC-24-0315.
The application of bacteria-nanomaterial hybrids in antitumor therapy.
Xiao S, Mu M, Feng C, Pan S, Chen N
J Nanobiotechnology. 2024; 22(1):536.
PMID: 39227831
PMC: 11373302.
DOI: 10.1186/s12951-024-02793-x.
Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancer.
Frame G, Leong H, Haas R, Huang X, Wright J, Emmenegger U
BJC Rep. 2024; 2(1):60.
PMID: 39184453
PMC: 11338830.
DOI: 10.1038/s44276-024-00085-3.
Oxygen-Enhanced MRI Detects Incidence, Onset, and Heterogeneity of Radiation-Induced Hypoxia Modification in HPV-Associated Oropharyngeal Cancer.
Dubec M, Price J, Berks M, Gaffney J, Little R, Porta N
Clin Cancer Res. 2024; 30(24):5620-5629.
PMID: 39142654
PMC: 11654720.
DOI: 10.1158/1078-0432.CCR-24-1170.
Nanotechnology as a new strategy for the diagnosis and treatment of gliomas.
Lei J, Huang Y, Zhao Y, Zhou Z, Mao L, Liu Y
J Cancer. 2024; 15(14):4643-4655.
PMID: 39006067
PMC: 11242339.
DOI: 10.7150/jca.96859.
Targeting drug resistance in glioblastoma (Review).
Sherman J, Bobak A, Arsiwala T, Lockman P, Aulakh S
Int J Oncol. 2024; 65(2).
PMID: 38994761
PMC: 11251740.
DOI: 10.3892/ijo.2024.5668.
Biomarker-driven molecular imaging probes in radiotherapy.
Li H, Gong Q, Luo K
Theranostics. 2024; 14(10):4127-4146.
PMID: 38994026
PMC: 11234278.
DOI: 10.7150/thno.97768.
Establishment and Application of Novel Hypoxia-driven Dual-reporter Model to Investigate Hypoxic Impact on Radiation Sensitivity in Human Nasopharyngeal Carcinoma Xenografts.
Dong J, Wang C, Zhang T, Yu X, Peng H, Xiao Z
J Cancer. 2024; 15(13):4345-4359.
PMID: 38947402
PMC: 11212076.
DOI: 10.7150/jca.96378.
[Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer
with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review].
Chen C, Yu Y, Huang M
Zhongguo Fei Ai Za Zhi. 2024; 27(5):399-404.
PMID: 38880928
PMC: 11183315.
DOI: 10.3779/j.issn.1009-3419.2024.102.19.